Fabrice Andre, Head of Research Division of Gustave Roussy, President Elect of the European Society for Medical Oncology, shared a post on X/Twitter:

“Thank you, The Lancet for taking this question seriously. Academic clinical trials should be evaluated mainly based on their IMPACT on patients, not only on innovation. Too many grant committees give too much weight to innovation vs impact, when it’s about funding clinical trials.”

Quoting The Lancet’s post:

“On our cover this week:
A Viewpoint on the need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology.”

View additional information.
Source: Fabrice Andre/X and The Lancet/X